Aridis Pharmaceuticals, Inc.

Equities

ARDS

US0403341045

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 02:59:13 2024-07-12 pm EDT			5-day change	1st Jan Change
0.06 ^USD	+8.89%		-21.57%	-14.41%

Jun. 24	Aridis Pharmaceuticals, Inc. Provides Corporate Update on Recent Developments	CI
Jun. 24	Aridis Pharmaceuticals, Inc. announced that it expects to receive $0.299 million in funding	CI

Aridis Pharmaceuticals, Inc. Appoints Steven Opal to its Scientific Advisory Board

November 26, 2014 at 08:20 am EST

Aridis Pharmaceuticals, Inc. announced the addition of Steven Opal, M.D., an internationally recognized key opinion leader in the areas of pneumonia and sepsis, to the company's scientific advisory board. Dr. Opal is a Professor of Medicine in the Infectious Disease Division of Alpert Medical School of Brown University and Chief of the Division of Infectious Diseases at Memorial Hospital of Rhode Island.

Latest news about Aridis Pharmaceuticals, Inc.

Aridis Pharmaceuticals, Inc. Provides Corporate Update on Recent Developments	Jun. 24	CI
Aridis Pharmaceuticals, Inc. announced that it expects to receive $0.299 million in funding	Jun. 23	CI
Aridis Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 03	CI
Certain Options of Aridis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-SEP-2023.	23-09-15	CI
Certain Warrants of Aridis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-SEP-2023.	23-09-15	CI
Certain Pre-Funded Warrant of Aridis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-SEP-2023.	23-09-15	CI
Certain Common Stock of Aridis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-SEP-2023.	23-09-15	CI
Aridis Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-09-14	CI
Aridis Pharmaceuticals, Inc. Announces Resignation as Chief Financial Officer	23-08-09	CI
Aridis Pharmaceuticals, Inc.(OTCPK:ARDS) dropped from S&P TMI Index	23-07-21	CI
Sector Update: Health Care Stocks Steady Premarket Tuesday	23-07-18	MT
Aridis Pharmaceuticals, European Regulator Agree on Pneumonia Phase 3 Study Parameters; Shares Jump Premarket	23-07-18	MT
Aridis Pharmaceuticals, Inc.(OTCPK:ARDS) dropped from NASDAQ Composite Index	23-07-18	CI
Aridis Pharmaceuticals Reaches Agreement for Phase 3 Study of Pneumonia Treatment in Europe; Shares Jump After Hours	23-07-17	MT
Aridis Receives Agreement from the European Medicines Agency on the Clinical Study Design and A Single Confirmatory Phase 3 Study of AR-301	23-07-17	CI
Aridis Pharma Shares Rise 33% After FDA Product Designation for AR-301	23-07-12	DJ
Aridis Pharmaceuticals Gets FDA Product Designation for AR-301	23-07-12	DJ
Aridisâ€™ AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDAâ€™s Qualified Infectious Diseases Product Designation	23-07-12	CI
Aridis Pharmaceuticals' AR-301 Eligible for Consideration Under FDA's Limited Population Pathway for Antibacterial and Antifungal Drugs	23-06-20	CI
Aridis Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-06-08	CI
Sector Update: Health Care Stocks Advancing Late Wednesday	23-05-31	MT
Sector Update: Health Care	23-05-31	MT
Top Midday Gainers	23-05-31	MT
Aridis Pharma Shares Double After FDA Clearance to Start AR-301 Pneumonia Study	23-05-31	DJ
Aridis Pharmaceuticals, Inc. Receives Agreement from the FDA on a Single Confirmatory Phase 3 Study of AR-301 and the Clinical Study Design	23-05-31	CI

Chart Aridis Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Aridis Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. The Company is focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs) to treat life-threatening infections. The Company's product pipeline is comprised of fully human mAbs targeting specific pathogens associated with life-threatening bacterial and viral infections, primarily hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and cystic fibrosis. The Company's lead product candidates, AR-301 and AR-320, target the alpha toxin produced by the gram-positive bacteria Staphylococcus aureus (S. aureus), a common pathogen associated with HAP and VAP. The Companyâs clinical development activities are primarily focused on AR-301, AR-320, and AR-501. Its MabIgX and lPEX discovery platforms enable the Company to rapidly screen, identify, and optimize fully human therapeutic mAb product candidates directly from the B-cells of patients.

Sector

Biotechnology & Medical Research

Calendar

2024-08-12 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
ARIDIS PHARMACEUTICALS, INC.	-14.41%	3.2M
VERTEX PHARMACEUTICALS INCORPORATED	+20.12%	126B
REGENERON PHARMACEUTICALS, INC.	+25.25%	119B
ARGENX SE	+25.56%	27.95B
BIONTECH SE	-19.51%	20.5B
GENMAB A/S	-14.36%	17.12B
BEIGENE, LTD.	-15.63%	16.1B
WUXI APPTEC CO., LTD.	-46.67%	14.97B
NEUROCRINE BIOSCIENCES, INC.	+11.89%	14.84B
SAREPTA THERAPEUTICS, INC.	+57.74%	14.38B

Bio Therapeutic Drugs